

## Cell-Vive™ GMP Recombinant Human TNF-α (carrier-free)

**Catalog# / Size** 570114 / 25 μg

570116 / 100 µg

Other Names Tumor necrosis factor-α, Cachectin, Necrosin, Macrophage cytotoxic factor (MCF),

Differentiation inducing factor (DIF), TNFSF2

**Description** TNF-α was originally described as an endotoxin-induced, macrophage-derived factor that

promotes hemorrhagic necrosis of solid tumors and the cachexia of chronic infections. TNF- $\alpha$  has also been implicated in a range of inflammatory, infectious, and malignant disorders. At the cellular level, TNF- $\alpha$  modulates a broad spectrum of responses including inflammation, immunoregulation, proliferation, apoptosis, and antiviral activity. In bone, the cytokine inhibits extracellular matrix deposition, stimulates matrix metalloprotease synthesis, and enhances production of osteoclastogenic cytokines such as M-CSF and RANKL. Chronic exposure to TNF- $\alpha$  in vivo increases osteoclastogenesis through two distinct mechanisms. TNF- $\alpha$  first affects osteoclastogenesis at the osteoclast precursor stage in the bone marrow by priming these cells to differentiate into cFms+/CD11b+/RANK+/- osteoclast progenitors via a RANKL/RANK independent mechanism. These osteoclast precursors then enter the blood and

peripheral tissues where they differentiate into mature osteoclasts in the presence of RANKL, and this process is accelerated by TNF. The role of TNF at this later stage of osteoclast differentiation is RANKL/RANK dependent. Importantly, TNF-α promotes bone resorption both in vitro and in vivo by enhancing the proliferation and differentiation of osteoclast precursors.

**Quality Statement** 

BioLegend Cell-Vive™ GMP Recombinant proteins are manufactured and tested in accordance with USP Chapter 1043, Ancillary Materials for Cell, Gene and Tissue-Engineered Products and Ph. Eur. Chapter 5.2.12 in a dedicated GMP facility compliant with ISO 13485:2016. Specifications and processes include:

- Low endotoxin level (≤ 0.1 EU/µg)
- Purity (≥ 95% or higher)
- Bioburden testing
- Mycoplasma testing
- · Batch-to-batch consistency
- Vendor qualification
- · Raw material traceability and documentation
- · Documented procedures and employee training
- Equipment maintenance and monitoring records
- Lot-specific certificates of analysis
- Quality audits per ISO 13485:2016
- QA review of released products

## **Product Details**

**Source** Human TNF- $\alpha$ , amino acids Val77-Leu233 (Accession# NM\_000594), was expressed in E. coli.

Molecular Mass The 157 amino acid recombinant protein has a predicted molecular mass of 17.35 kD. The DTT-

reduced protein and non-reduced protein migrate at approximately 16 kD by SDS-PAGE. The N-

terminal amino acid is Val.

N-terminal

Sequence Analysis

Val-Arg-Ser-Ser-(Ser)-Arg-Thr-Pro-Ser-Asp

**Purity** ≥ 95%, as determined by Coomassie stained SDS-PAGE

Formulation 0.1 μm filtered protein solution is in 10 mM NaH<sub>2</sub>PO<sub>4</sub>, 150 mM NaCl, pH 7.2.

Endotoxin Level Less than or equal to 0.1 EU per µg protein as determined by the LAL method

Residual Host Cell Protein Content ≤ 0.500 ng/µg by ELISA

Concentration 500 μg/mL

Storage & Handling

Unopened vial can be stored between 2°C and 8°C for up to 2 weeks, at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% endotoxinfree BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week or stored at -20°C or colder for up to 3 months. **Avoid repeated freeze/thaw cycles.** 

**Activity** 

ED<sub>50</sub> = 0.01 - 0.085 ng/mL as determined by the dose-dependent cytotoxicity of L929 cells stimulated with actinomycin D. The specific activity of Cell-Vive<sup>TM</sup> GMP Recombinant Human TNF-α (carrier-free) is >1.5 x  $10^7$  IU/mg when compared against the  $3^{rd}$  WHO International Standard for Human TNF-α (NIBSC code: 12/154).

**Application** 

Bioassay Cell Culture

**Application Notes** 

BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue-ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are verified in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at tech@biolegend.com.

Disclaimer

BioLegend Cell-Vive™ GMP Recombinant proteins are for research use only. Suitable for *ex vivo* cell processing. Not for injection or diagnostic or therapeutic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

## **Antigen Details**

Structure TNF superfamily

Distribution It is produced primarily by macrophages, and it is also expressed by activated T cells, B cells, NK

cells, and neutrophils.

**Function** Type II integral membrane protein processed by TACE for secretion; upregulated by interferons, IL-

2, GM-CSF, substance P, bradykinin, PAF, immune complexes, cyclooxygenase; downregulated by

IL-6, TGF- $\beta$ , vitamin D3, prostaglandin E2, PAF antagonists

**Interaction** Monocytes, neutrophils, macrophages, T cells, fibroblasts, endothelial cells, osteoclasts,

adipocytes, astroglia, microglia

Ligand/Receptor TNFRSF1A (TNF-R1, CD120a, TNFR-p60 Type β, p55); TNFRSF1B (TNF-R2, CD120b, TNFR-

p80 Type A, p75)

**Bioactivity** Measured by its ability to induce cytotoxicity of L929 cells stimulated with actinomycin D

Biology Area Cell Biology, Immunology, Innate Immunity, Neuroinflammation, Neuroscience

Molecular Family Cytokines/Chemokines

**Antigen References** 

1. Boyce BF, et al. 2005. J Med 54:127-131.

2. Lam J, et al. 2000. J Clin Invest 106:1481-1488.

3. Udagawa N, et al. 2002. Arthritis Res 4:281-289.

4. Kwon J, et al. 1993. Gene 132:227-236.

5. Harth S, et al. 2019. MAbs. 11:178.

6. de Oliveira Mann CC, et al. 2019. Cell Rep. 27:1165.

7. Anderson NR, et al. 2019. Cell Adh Migr. 13:163.


8. Zhichao Fan, et al. 2019. Cell Rep. 26(1):119-130.

9. VanDussen KL, et al. 2019. Stem Cell Res. 37:101430.

10. Hurrell BP, et al. 2019. Cell Rep. 29:4509.

Gene ID 7124

## **Product Data**



GMP recombinant human TNF- $\alpha$  induces cytotoxicity of L929 cells in a dosedependent manner with an ED<sub>50</sub> range of 0.01 - 0.085 ng/mL.

For Research Use Only. Suitable for ex vivo cell processing. Not for injection or diagnostic or therapeutic use.

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user's intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587